Hyperactivity in Senile Dementia

Finestone, Douglas H.; Larson, David B.; Whanger, Alan D.; Cavenar, Jesse O.

doi:10.1111/j.1532-5415.1982.tb01690.x

Cited by 10 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, it is widely recognized that patients with dementia commonly present clinically with behavioral symptoms in addition to cognitive deficits (tiamilton and Bennett, 1962b;Finestone et a/., 1982;Petrie et al, 1982;Salzman, 1982;Helms, 1985;Risse and Barnes, 1986). Often, these behavioral symptoms lead to empiric treatment with neuroleptic medications.…”

Section: Discussionmentioning

confidence: 95%

“…Most earlier reviews of the pharmacologic treatment of dementia have focused on attempts to reverse the cognitive dysfunction with various classes of drugs including vasodilators, psychostimulants, neurotransmitter precursors, neuropeptides and the neurotropics (Prien, 1973;Raskind and Storrie, 1980;Cole, 1980;Bartus et al, 1982). Yet, it is widely recognized that patients with dementia commonly present clinically with behavioral symptoms in addition to cognitive deficits (tiamilton and Bennett, 1962b;Finestone et a/., 1982;Petrie et al, 1982;Salzman, 1982;Helms, 1985;Risse and Barnes, 1986). Often, these behavioral symptoms lead to empiric treatment with neuroleptic medications.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neuroleptics in the treatment of dementia

Sunderland¹,

Silver²

1988

Int J Geriat Psychiatry

View full text Add to dashboard Cite

SUMMARYThe authors review the history of neuroleptic treatment in dementia. The initial review of 34 studies published since 1954 was limited to the 20 double-blind and/or placebo-controlled studies. Sixty per cent of the studies revealed generally positive clinical results in demented patients following neuroleptic treatment. Acute side-effects were not reported to be more prevalent or severe than in other psychiatric populations and included sedation, orthostatic hypotension, extrapyramidal reactions, and various anticholinergic symptoms. Careful assessment of the cognitive effects following neuroleptics, particularly those with known anticholinergic properties, was not performed in most of these studies and should be a focus of future prospective studies in this population. Nonetheless, it does appear that neuroleptics have a role in the treatment of patients with dementia. When used at low doses for specific purposes (i.e. treatment of agitation, hyperactivity, hallucinations, or hostility), they can both safe and effective in this population.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Neuroleptics in the treatment of dementia

Sunderland¹,

Silver²

1988

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…Neuroleptic medications have become the mainstay in the treatment of agitation in the elderly demented patient 14 . Uncontrolled studies and case reports have claimed that low doses of neuroleptics produce dramatic improvement in a wide variety of behavioral disturbances in geriatric patients residing in nursing homes or in state hospitals 15–25 . However, the majority of these claims are difficult to substantiate because they were based primarily on impressionistic outcome measures in populations that often included patients with functional psychiatric disorders.…”

Section: Neurolepticsmentioning

confidence: 99%

Pharmacologic Treatment of Agitation Associated With Dementia

Risse

Barnes

1986

J American Geriatrics Society

120

View full text Add to dashboard Cite

Pharmacotherapy of aggressive or agitated behaviors in the dementia patient has not been studied extensively, despite the prevalence of this problem. Neuroleptics have the most support for efficacy, with shorter acting benzodiazepines demonstrating benefit on occasion. However, studies done to date indicate that these drugs are effective only for a minority of patients and that side effects frequently make patients worse. Other medications, such as propranolol, carbamazepine, or lithium, may be helpful, but their efficacy in dementia patients has not been demonstrated in placebo-controlled studies. Until such studies are done, their use is most appropriate in special patient groups or in patients who have failed neuroleptic or benzodiazepine treatment. More studies are needed in elderly patients evaluating effectiveness of pharmacologic agents in specific types of dementia, particularly Alzheimer's disease. Most studies done to date have been of relatively short duration, usually two months or less. Because these medications often are given to dementia patients for prolonged periods, studies are needed to define the long-term clinical efficacy of these agents. In the clinical setting, these agents should be reduced periodically or discontinued to determine ongoing need. In addition, environmental, social, or behavioral methods of reducing agitated behaviors need to be explored as an adjunct to any medication trial.

show abstract

“…The behaviour referred to by this term is sometimes also called wandering. For example, in a study titled 'Hyperactivity in senile dementia', Finestone et al, (1982) give as an example of hyperactivity a woman who: 'began to pace constantly about her house, often wandering off. The term 'agitation' too maybe applied to behaviour which others call wandering (Cohen-Mansfield and Billig, 1986).…”

mentioning

confidence: 99%

The nature of wandering in dementia: A community‐based study

Hope¹,

Fairburn²

1990

Int J Geriat Psychiatry

View full text Add to dashboard Cite

SUMMARYWandering in dementia causes major difficulties for both patients and their carers. The term 'wandering', however, is vague and has no specific meaning. The behaviour of 29 patients in the community with dementia who had been classed as 'wanderers' was studied. The subjects were assessed using a semistructured interview with a carer. The findings show that the term 'wandering' covers a wide range of distinct behavioural abnormalities. A descriptive typology of wandering is proposed and the rates of each type are given. It is suggested that five fundamental components underlie the various types of wandering.KEY worn-Dementia, Alzheimer's disease, behavioural problems, wandering.

show abstract

Hyperactivity in Senile Dementia

Cited by 10 publications

References 0 publications

Neuroleptics in the treatment of dementia

Neuroleptics in the treatment of dementia

Pharmacologic Treatment of Agitation Associated With Dementia

The nature of wandering in dementia: A community‐based study

Contact Info

Product

Resources

About